Drug Profile

HOPE 777

Alternative Names: HOPE-777

Latest Information Update: 28 Mar 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator NeoPharm Co
Developer Hope Biosciences
Class Antineoplastics; Heterocyclic compounds
Mechanism of Action Axl receptor tyrosine kinase inhibitors; Proto-oncogene protein c-mer inhibitors; RON protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

No development reported Cancer

Most Recent Events

28 Mar 2021 No recent reports of development identified for preclinical development in Cancer in USA
01 Feb 2017 Hope Biosciences enters into a licensing agreement with NeoPharm Co. Ltd and acquires exclusive and worldwide rights to develop and commercialise HOPE 777 for the treatment of cancer
01 Feb 2017 Preclinical trials in Cancer in USA (unspecified route)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com